Bli medlem
Bli medlem

Du är här

2019-12-20

WntResearch: WntResearch announces few reported side effects from the NeoFox study; Foxy-5 treatment considered safe and we...

The Data Safety Monitoring Board (DSMB) for WntResearch's NeoFox study
convened today to analyze the reported side effects from the first
ten patients, which on average have received 7 weeks of treatment
with Foxy-5 and undergone surgery. As expected, the results show few
side effects, and due to this positive analysis the study can proceed
according to plan.

As previously disclosed, WntResearch has been requested to perform an
initial safety assessment as part of the approval process for the
study's initiation, since ten patients have undergone surgery during
the Foxy-5 administration period. The DSMB group consists of highly
experienced clinical researchers: Professor Jan Vermorken, Professor
Andrés Cervantes and Dr Ramon Salazar, together with MS-oncology's
Chief Medical Officer, Stephan Winckels. All of them consider the
side effect profile to be favorable. The rate of reported side
effects which are considered to be attributable to the use of Foxy-5
is low. All of these side effects are mild, and not recurring in
continued treatment. No patients have terminated the study due to
side effects.

"This first safety analysis on patients within the target group
strengthens our assessment that Foxy-5 is a safe product, and
confirms the outcome of previous toxicological studies. The result is
significant for primarily two reasons; that Foxy-5 can be
administered without risk to otherwise healthy cancer patients, and
that Foxy-5 so far has not shown any indication to affect the healing
process after surgery. A safe product, practically void of side
effects, is a prerequisite to secure approval as a future neoadjuvant
treatment for patients," says WntResearch's CEO, Peter Morsing.

For more information, please contact:

Peter Morsing, CEO, WntResearch AB
E-mail: pm@wntresearch.com

Telephone: +46 727 200711

This information is information that WntResearch AB is obliged to make
public

pursuant to the EU Market Abuse Regulation and the Securities Markets
Act. The information was submitted for publication, through the
agency

of the contact person set out above, on December 20, 2019.

About WntResearch

WntResearch is developing an entirely new kind of cancer drug, which
inhibits the tumour cells' ability to spread through the body and
metastasize. The majority of cancer deaths are due to metastases, and
there are no therapies available that can prevent that. Foxy-5, the
Company's most advanced drug candidate, is a peptide that mimics the
body's own WNT5A protein. In preclinical trials, Foxy-5 has
demonstrated ability to suppress the mobility and invasive power of
cancer cells, and thus to inhibit metastasis. Phase 1 studies on
patients with colon, prostate and breast cancer have demonstrated a
good safety profile and favourable pharmacokinetics, and early data
indicates biological activity. A Phase 2 multicenter study was
recently initiated on patients with colon cancer, in order to study
the anti-metastasizing efficacy of Foxy-5. WntResearch's share is
listed on Spotlight Stock Market. For more information, please visit:
www.wntresearch.com

-----------------------------------------------------------
http://publish.ne.cision.com//Release/ViewReleaseHtml/A47B5EBAC9E944B6E0...
https://mb.cision.com/Main/11610/2996899/1165829.pdf

Författare AktieTorget News

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.